SK Biopharmaceuticals Co., Ltd.

KSE 326030.KS

SK Biopharmaceuticals Co., Ltd. Market Capitalization on January 14, 2025: USD 5.91 B

SK Biopharmaceuticals Co., Ltd. Market Capitalization is USD 5.91 B on January 14, 2025, a 5.95% change year over year. Market capitalization represents total company value in stock market; higher suggests larger, more established company.
  • SK Biopharmaceuticals Co., Ltd. 52-week high Market Capitalization is USD 7.18 B on October 15, 2024, which is 21.48% above the current Market Capitalization.
  • SK Biopharmaceuticals Co., Ltd. 52-week low Market Capitalization is USD 4.25 B on June 27, 2024, which is -28.16% below the current Market Capitalization.
  • SK Biopharmaceuticals Co., Ltd. average Market Capitalization for the last 52 weeks is USD 5.45 B.
Key data
Date Market Capitalization Share Price Price to Earnings Ratio (P/E) Price to Sales Ratio (P/S)
Market news
Loading...
KSE: 326030.KS

SK Biopharmaceuticals Co., Ltd.

CEO Mr. Dong Hoon Lee
IPO Date July 2, 2020
Location South Korea
Headquarters 221, Pangyoyeok-ro
Employees 241
Sector Health Care
Industries
Description

SK Biopharmaceuticals Co., Ltd., a pharmaceutical company, engages in the research, discovery, and development of drugs for the treatment of central nervous system disorders. The company is developing Cenobamate for the treatment of epilepsy; Solriamfetol for the treatment of excessive daytime sleepiness in narcolepsy or obstructive sleep apneal; Carisbamate that is in Phase 1b/2 trials to treat lennox-gastaut syndrome; and Relenopride, which is in Phase 2 clinical trials to treat rare neurological disease. It is also developing SKL13865 that is in Phase 1 clinical trials to treat attention deficit/hyperactivity disorder; SKL20540, which is in Phase 1 clinical trials for the treatment of schizophrenia; SKL-PSY that is in Phase 1 clinical trials to treat bipolar disorder; and SKL24741, which is in Phase 1 clinical trials for the treatment of epilepsy. The company was founded in 2011 and is headquartered in Seongnam, South Korea. SK Biopharmaceuticals Co., Ltd. operates as subsidiary of SK Inc.

Similar companies

035720.KS

Kakao Corp.

USD 25.13

1.70%

000100.KS

Yuhan Corporation

USD 89.21

-4.31%

207940.KS

Samsung Biologics Co.,Ltd.

USD 698.37

1.93%

068270.KS

Celltrion, Inc.

USD 125.83

1.12%

302440.KS

SK bioscience Co.,Ltd.

USD 33.55

-1.07%

StockViz Staff

January 15, 2025

Any question? Send us an email